Dothip Tablets are available in strengths containing Dothiepin Hydrochloride 25 mg, 50 mg, and 75 mg.

Dothip Tablets contain Dothiepin Hydrochloride, a tricyclic antidepressant (TCA) with antidepressant, anxiolytic, sedative, antihistaminic, and anticholinergic properties. The drug enhances central neurotransmission by increasing the availability of noradrenaline and serotonin at synaptic nerve endings. Dothip is effective in the management of depressive disorders associated with anxiety and provides symptomatic relief in patients with psychotic and neurotic depression.

Dothip Tablets are indicated for the treatment of psychotic depression, neurotic depression, anxiety associated with depression, and depressive disorders requiring tricyclic antidepressant therapy.

Dothiepin Hydrochloride is a tricyclic antidepressant that increases the synaptic availability of the neurotransmitters noradrenaline and serotonin (5-hydroxytryptamine) by inhibiting their reuptake at central noradrenergic nerve terminals. Enhancement of these neurotransmitters improves mood and relieves depressive symptoms. In addition to its antidepressant effects, Dothiepin possesses significant anticholinergic, antihistaminic, and central sedative properties, which contribute to its anxiolytic and sedative actions.

Treatment is generally initiated with 25 mg three times daily for one to two weeks. If the clinical response is inadequate, the daily dose may be increased by 25 mg to 50 mg at intervals of one to two weeks according to patient response and tolerability. The total daily dose should not exceed 200 mg. Once an effective maintenance dose has been established, up to 150 mg may be administered as a single bedtime dose. As Dothiepin may cause drowsiness, the major portion of the daily dose should preferably be taken at night or as directed by the treating physician.

Dothip Tablets are contraindicated in patients with known hypersensitivity to Dothiepin or any component of the formulation, epilepsy due to the risk of lowering the seizure threshold, hepatic failure, and during the acute recovery phase following myocardial infarction because of the potential for cardiac conduction abnormalities and arrhythmias. The drug should not be administered concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy because of the risk of severe central nervous system excitation, hyperthermia, coma, and other serious reactions.